RXFP1 and systemic sclerosis: Our study suggests that transcriptional modulation of RXFP1 in fibroblasts from patients with fILD may be one of the strategies to restore RXFP1 expression and the responsiveness to relaxin-based antifibrotic therapies in patients with IPF and SSc.